doi:10.1038/s41598-023-50537-yengMartínez-Domínguez, Samuel J.García-Mateo, SandraSainz-Arnal, PilarMartínez-García, JavierGallego-Llera, BeatrizLozano-Limones, María JesúsHidalgo, SandraGargallo-Puyuelo, Carla J.Latre-Santos, MartaNocito-Colon, Maria Mercedes LourdesMartínez-Lostao, LuisRefaie, EngyArroyo-Villarino, Maria Teresadel Rio-Nechaevsky, MarcelaRamirez-Labrada, ArielPardo, JuliánGomollón, FernandoBaptista, Pedro M.Unravelling the cellular response to the SARS-COV-2 vaccine in inflammatory bowel disease patients on biologic drugsART-2023-136838Suboptimal vaccine response is a significant concern in patients with Inflammatory Bowel Disease (IBD) receiving biologic drugs. This single-center observational study involved 754 patients with IBD. In Phase I (October 2020-April 2021), 754 IBD participants who had not previously received the SARS-CoV-2 vaccine, underwent blood extraction to assess the seroprevalence of SARS-CoV-2 infection and IBD-related factors. Phase II (May 2021-October 2021) included a subgroup of 52 IBD participants with confirmed previous SARS-CoV-2 infection, who were studied for humoral and cellular response to the SARS-CoV-2 vaccine. In Phase I, treatment with anti-TNF was associated with lower rates of seroconversion (aOR 0.25 95% CI [0.10–0.61]). In Phase II, a significant increase in post-vaccination IgG levels was observed regardless of biologic treatment. However, patients treated with anti-TNF exhibited significantly lower IgG levels compared to those without IBD therapy (5.32 ± 2.47 vs. 7.99 ± 2.59 U/ml, p = 0.042). Following vaccination, a lymphocyte, monocyte, and NK cell activation pattern was observed, with no significant differences between patients receiving biologic drugs and those without IBD treatment. Despite lower seroprevalence and humoral response to the SARS-CoV-2 vaccine in patients treated with anti-TNF, the cellular response to the vaccine did not differ significantly from that patients without IBD therapy.2023http://zaguan.unizar.es/record/13141110.1038/s41598-023-50537-yhttp://zaguan.unizar.es/record/131411oai:zaguan.unizar.es:131411info:eu-repo/grantAgreement/ES/AEI/PID2020-113963RB-I00info:eu-repo/grantAgreement/ES/DGA-FEDER/B29-17Rinfo:eu-repo/grantAgreement/ES/ISCIII/CB21-13-100087Scientific reports (Nature Publishing Group) 13, 1 (2023), 23061 [11 pp.]byhttp://creativecommons.org/licenses/by/3.0/es/info:eu-repo/semantics/openAccess